A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients

Trial Profile

A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms RE-ARRANGE
  • Most Recent Events

    • 24 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress,160 of 295 planned pa- tients have been recruited at the end of March 2017 (first patient 15 July 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top